1. Nudix hydrolase 1 is a prognostic biomarker in hepatocellular carcinoma
- Author
-
Jiong Bi, Jieyi Ma, Zheng Yu, Wen Li, Yucheng Hou, Longjuan Zhang, Ning Ma, Qifeng Ou, Ziming Wang, Rongchang Wang, Qiao Su, Fan Chen, and Xiao-Hui Huang
- Subjects
Male ,Aging ,Carcinoma, Hepatocellular ,medicine.drug_class ,Biology ,survival analysis ,nomogram ,medicine ,Biomarkers, Tumor ,Gene silencing ,Humans ,Gene ,Survival analysis ,Neoplasm Staging ,Bile acid ,Liver Neoplasms ,Cell Biology ,hepatocellular carcinoma ,DNA, Neoplasm ,Cell cycle ,Middle Aged ,medicine.disease ,Prognosis ,digestive system diseases ,Phosphoric Monoester Hydrolases ,Biomarker (cell) ,Up-Regulation ,NUDT1 ,Gene Expression Regulation, Neoplastic ,DNA Repair Enzymes ,Hepatocellular carcinoma ,Cancer research ,biomarker ,Transmembrane transporter activity ,Female ,Research Paper - Abstract
We investigated the prognostic significance of Nudix hydrolase 1 (NUDT1) in hepatocellular carcinoma (HCC). NUDT1 mRNA and protein levels were significantly higher in HCC tissues than normal liver tissues. The level of NUDT1 expression correlated with tumor grade, stage, size, differentiation, degree of vascular invasion, overall survival (OS), and disease-free survival (DFS) in HCC patients. Multivariate analysis showed that NUDT1 expression was an independent prognostic factor for OS and DFS in HCC patients. We constructed a prognostic nomogram with NUDT1 expression, AFP levels, vascular invasion, Child-Pugh classification, age, sex, AJCC staging, and tumor differentiation as variables. This nomogram was highly accurate in predicting the 5-year OS of HCC patients (c-index= 0.709; AUC= 0.740). NUDT1 silencing in HCC cells significantly reduced their survival, colony formation, migration, and invasiveness. Gene set enrichment analysis showed that biological pathways related to cell cycle, fatty acid metabolism, bile acid and bile salt metabolism, and PLK1 signaling were associated with NUDT1, as were the gene ontology terms "DNA binding transcription activator activity," "RNA polymerase II," "nuclear division," and "transmembrane transporter activity." Our study thus demonstrates that NUDT1 is a prognostic biomarker with therapeutic potential in HCC patients.
- Published
- 2020